Perthera

Perthera is a leader in AI-driven precision oncology, offering a comprehensive platform that integrates multi-omic testing results and patient history to match cancer patients with ranked therapy options. Its core product, the Perthera Report®, is used by oncologists to optimize treatment decisions and streamline clinical workflows, while its data pipeline supports real-world evidence generation and clinical trial matching. The company has established a significant footprint, with its platform reportedly used in 600 hospitals/clinics and by 10% of US medical oncologists, and it demonstrates strong clinical impact metrics, including a 2.4x improvement in progression-free survival for its patients.

The Perthera Precision Oncology Platform is an AI-powered system that integrates a patient's cancer treatment history and multi-omic molecular data (genomic, transcriptomic, etc.) to generate a personalized clinical report (Perthera Report®) with ranked therapy options. It includes modules for a Virtual Molecular Tumor Board, clinical trial matching for CROs, and a real-world evidence data pipeline enhanced by proprietary AI analysis.

Perthera competes in the crowded precision oncology informatics market against companies like Tempus, Foundation Medicine (Roche), and Caris Life Sciences, which also combine molecular testing with data analytics. Its differentiation lies in its specific focus on the ranked therapy report for clinical decision-making at the point of care and its claimed integration into the workflows of a substantial network of US oncologists.